Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
COSELA® granted full approval by NMPA
Simcere Zaimig announces new IND approval of SIM0237, an anti-PD-L1/IL-15 bispecific antibody by NMPA
2023 ESMO：Simcere Zaiming will showcase latest clinical data regarding 3 three innovative products and 3 pipeline candidates
Simcere Pharmaceutical Enters into a Cooperation Agreement with AnDiCon on Anti-influenza Innovative Drug ADC189
Simcere Zaiming to present the latest clinical progresses of three products in its portfolio at WCLC 2023
The First Subject Dosed with SIM0278, an Innovative IL-2 mu-Fc Independently Developed by Simcere Pharmaceutical
Positive Results from Phase II Clinical Study of JAK1 Inhibitor for AS Treatment Jointly Introduced by Simcere Pharmaceutical and Lynk Pharmaceuticals
Simcere Zaiming Partners with MabPharm on anti-EGFR Monoclonal Antibody CMAB009 in China
COSELA® new indication NDA accepted by China NMPA